Skip to main content

Table 2 Prevalence of Cervical, Vulvar, Anal and Oral Human papillomavirus infections among sexually active women from the general population in two communities in Ibadan, Nigeria (N = 310)

From: Prevalence and genotype specific concordance of oro-genital and anal human papillomavirus infections among sexually active Nigerian women

Variable

Cervical sample

Vulvar sample

Anal sample

Oral sample

n/N1

Prevalence % [95% CI]

n/N

Prevalence (%) [95% CI]

n/N

Prevalence (%) [95% CI]

n/N

Prevalence (%) [95% CI]

Any HPV genotype

 

p = 0.014*

 

p = 0.523

 

p = 0.021*

 

p = 0.669

 18–24 years

79/118

66.9 (57.8–75.3)

86/121

71.1 (62.1–79.0)

74/120

61.7 (52.4–70.4)

20/111

18.0 (11.4–26.4)

 25–34 years

62/100

62.0 (51.7–71.5)

68/100

68.0 (57.9–77.0)

57/97

58.9 (48.3–68.7)

15/92

16.3 (9.4–25.5)

 35–45 years

41/87

47.1 (36.3–58.1)

56/88

63.6 (52.7–73.6)

41/86

47.7 (36.8–58.7)

11/83

13.3 (6.8–22.5)

 Overall

182/305

59.7 (53.9–65.2)

210/309

68.0 (62.4–73.1)

172/303

56.8 (51.0–62.4)

46/286

16.1 (12.0–20.9)

HPV classification by IARC2 Class 1—Carcinogenic3

 

p = 0.074*

 

p = 0.026*

 

p = 0.230*

 

p = 0.967

 18–24 years

58/118

49.2 (39.8–58.5)

65/121

53.7 (44.4–62.8)

50/120

41.7 (32.7–51.0)

11/111

9.9 (5.1–17.0)

 25–34 years

41/100

41.0 (31.3–51.3)

48/100

48.0 (37.9–58.2)

38/97

39.2 (29.4–49.6)

9/92

9.9 (4.6–17.8)

 35–45 years

29/87

33.3 (23.6–44.3)

36/88

40.9 (30.5–51.9)

26/86

30.2 (20.8–41.1)

9/83

10.8 (5.1–19.6)

 Overall

128/305

42.0 (36.4–47.7)

149/309

48.2 (42.5–53.9)

114/303

37.6 (32.1–43.3)

29/286

10.1 (6.9–14.2)

Class 2A—Probable carcinogenic4

 

p = 0.8355

 

p = 0.954

 

p = 0.094b

 

p = 0.749b

 18–24 years

5/118

4.2 (1.4–9.6)

9/121

7.4 (3.5–13.7)

8/120

6.7 (2.9–12.7)

1/111

0.9 (0.02–4.9)

 25–34 years

4/100

4.0 (1.1–9.9)

8/100

8.0 (3.5–15.2)

1/97

1.0 (0.0–5.6)

0/92

0

 35–45 years

5/87

5.7 (1.9–12.9)

6/88

6.8 (2.5–14.3)

5/86

5.8 (1.9–13.0)

1/83

1.2 (0.03–6.5)

 Overall

14/305

4.6 (2.5–7.6)

23/309

7.4 (4.8–11.0)

14/303

4.6 (2.5–7.6)

2/286

0.7 (0.08–2.5)

Class 2B—Possible carcinogenic6

 

p = 0.006*

 

p = 0.102

 

p = 0.265

 

p = 0.966

 18–24 years

54/118

45.8 (36.6–55.2)

60/121

49.6 (40.4–58.8)

47/120

39.2 (30.4–48.5)

7/111

6.3 (2.6–12.6)

 25–34 years

40/100

40.0 (30.3–50.3)

50/100

50.0 (39.8–60.2)

40/97

41.2 (31.3–51.7)

6/92

6.5 (2.4–13.7)

 35–45 years

21/87

24.1 (15.6–34.5)

32/88

36.4 (26.4–47.3)

26/86

30.2 (20.8–41.1)

6/83

7.2 (2.7–15.1)

 Overall

115/305

37.7 (32.2–43.4)

142/309

46.0 (40.3–51.7)

113/303

37.3 (31.8–43.0)

19/286

6.6 (4.0–10.2)

Class 3—Unclassified7

 

p = 0.019*

 

p = 0.154

 

p = 0.597

 

p = 0.835

 18–24 years

14/118

11.9 (6.6–19.1)

16/121

13.2 (7.8–20.6)

12/120

10.0 (5.3–16.8)

4/111

3.6 (0.9–9.0)

 25–34 years

5/100

5.0 (1.6–11.3)

8/100

8.0 (3.5–15.2)

6/97

6.2 (2.3–13.0)

2/92

2.2 (0.3–7.6)

 35–45 years

2/87

2.3 (0.3–8.1)

5/88

5.7 (1.9–12.8)

7/86

8.1 (3.3–16.1)

3/83

3.6 (0.8–10.2)

 Overall

21/305

6.9 (4.3–10.3)

29/309

9.4 (6.4–13.2)

25/303

8.3 (5.4–11.9)

9/286

3.1 (1.4–5.9)

Any HR-HPV genotypes8

 

p = 0.095*

 

p = 0.142*

 

p = 0.243

 

p = 0.965

 18–24 years

60/118

53.1 (44.7–61.3)

69/121

59.3 (51.0–67.3)

53/120

44.2 (35.1–53.5)

12/111

10.8 (5.7–18.1)

 25–34 years

44/100

38.0 (28.1–48.8)

51/100

44.6 (34.2–55.3)

38/97

39.2 (29.4–49.6)

9/92

9.8 (4.6–17.8)

 36–45 years

31/87

33.3 (22.2–46.0)

38/67

41.8 (29.8–54.5)

28/86

32.6 (22.8–43.5)

9/83

10.8 (5.1–19.6)

 Overall

135/305

44.3 (38.6–50.0)

158/309

51.1 (45.4–56.8)

119/303

39.3 (33.7–45.0)

30/286

10.5 (7.2–14.6)

Any LR-HPV genotype9

 

p = 0.001*

 

p = 0.047*

 

p = 0.495

 

p = 0.891

 18–24 years

60/118

50.8 (41.5–60.2)

66/121

54.5 (45.2–63.6)

56/120

46.7 (37.5–56.0)

11/111

9.9 (5.1–17.0)

 25–34 years

41/100

41.0 (31.3–51.3)

50/100

50.0 (39.8–60.2)

44/97

45.4 (35.2–55.8)

8/92

8.7 (3.8–16.4)

 35–45 years

22/87

25.3 (16.6–35.7)

33/88

37.5 (27.4–48.5)

33/86

38.4 (28.1–49.5)

9/83

10.8 (5.1–19.6)

 Overall

123/305

40.3 (34.8–46.1)

149/309

48.2 (42.5–53.9)

133/303

43.9 (38.2–49.7)

28/286

9.8 (6.6–13.8)

Multiple HPV genotypes infection10

 

p < 0.001*

 

p = 0.012*

 

p = 0.014*

 

p = 0.7215

 18–24 years

54/118

45.8 (36.6–55.2)

59/121

48.7 (39.6–58.0)

51/120

42.5 (33.5–51.9)

4/111

3.6 (1.0–9.0)

 25–34 years

29/100

29.0 (20.4–38.9)

42/100

42.0 (32.2–52.3)

31/97

32.0 (22.9–42.2)

4/92

4.3 (1.2–10.8)

 35–45 years

18/87

20.7 (12.7–30.7)

25/88

28.4 (19.3–39.0)

20/86

23.3 (14.8–33.6)

5/83

6.0 (2.0–13.5)

 Overall

101/305

33.1 (27.9–38.7)

126/309

40.8 (35.2–46.5)

102/303

33.7 (28.4–39.3)

13/286

4.5 (2.4–7.6)

  1. 1n/N—number of samples with positive HPV infection as numerator and total samples with valid result as denominator; 2IARC—International Agency for Research on Cancer (*HPV genotypes in IARC classification that are not included in the Anyplex II HPV28 platform); 3Class 1 IARC HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59; 4Class 2A IARC HPV—68; 5Bartlett’s test for equal variances were significant (p < 0.05); 6Class 2B IARC HPV—5*, 8*, 26, 30*, 34*, 40, 42, 43, 44, 53, 54, 55*, 61, 66, 67*, 69, 70, 71*, 72*, 73, 81*, 82, 83*, 84*, 85*, 97*, IS39* and CP6108*; 7Class 3 IARC HPV—6, 11; 8HR-HPV Group—Class 1 IARC HPV and Class 2A IARC HPV; 9LR-HPV—Class 2b IARC and Class 3 IARC; 10Multiple HPV infection-detection of two or more genotypes of HPV by Anyplex II HPV28 from a sample. All invalid samples were excluded from the descriptive analysis
Back to article page